Fig. 1.
![Fig. 1. cPLA2 activity in neutrophil lysates of patients with sepsis or with sepsis+bacteremia. / DTT-resistant cPLA2 activity is measured by [14C]AA release from PC vesicles using neutrophil lysates from patients with sepsis or sepsis+bacteremia (“During”) and after recovery (“After”).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/95/2/10.1182_blood.v95.2.660/6/bloo00211001x.jpeg?Expires=1735858262&Signature=0VK62lU6BQgPssf6ZQxTe9mFCSZhRWzm7veVYLkd6-tSqUjHIvYyT~yFeCHZft4DkqVAMAwRradSVisg43ldXt1gtU6fHYg1xZWZXY7zbxDeFhHfPxZ1sA3AygOdXh85NL-j9bMWWJdjVUY~xIXBT8dQRNjWXgHjv2wgZhM-iIkiOBYmcFNudUABx2sOtVDmRTXGHnTk4iB8duL9r-tkaPReSgbm1aP8quuukuSUDoWMhzriSBB4ZopWzS5F1nZ5ffxlFGO2wXdKyZPVcib4dDJUB3DAndpE40cjOTi2ztx7Gzxu65ATbhj1Qk2UGOVsESk2U86o-75x3ZLl9MOoJQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
cPLA2 activity in neutrophil lysates of patients with sepsis or with sepsis+bacteremia.
DTT-resistant cPLA2 activity is measured by [14C]AA release from PC vesicles using neutrophil lysates from patients with sepsis or sepsis+bacteremia (“During”) and after recovery (“After”).
